Fig. 1: Clinical characterization of CREB5 in BC subtypes.

Box plots showing CREB5 median expression across A TCGA and B METABRIC datasets with the boxes representing the ends of the first and third quartiles in breast cancer molecular subtypes. Red dotted line denotes the global median while blue dotted lines are global standard deviations. C Percent of tumors with CREB5 amplifications or overexpression in BLBC as compared to all other BC subtypes in the same two datasets. Overexpression is defined by a z-score >2 and amplifications are defined by cBioPortal parameters. D Kaplan–Meier plot comparing overall survival of CREB5 high (red line) versus low (black line) BLBC patients (n = 309) from KMPlot.com. E BCBMs acquired by Cosgrove et al.¹² are stratified by BC subtypes including basal (n = 16), HER2 (n = 9), luminal A (n = 11), and luminal B (n = 8). Median CREB5 expression across subtypes are shown in a box plot with whiskers extending to minimum and maximum values. *p < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001, ns not significant. F Waterfall plot shows the percent change of CREB5 expression in each patient from the primary BC biopsy to the BCBM biopsy in the same dataset.